 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
Gilead Sciences, Foster City, California.
Correspondence to Dr. Tomas Cihlar, Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404. Phone: 650-522-5637; Fax: 650-522-5890; E-mail: tomas_cihlar{at}gilead.com
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Recently, we (9) and others (10,11) have independently reported the cloning and expression of the human renal organic anion transporter 1 (hOAT1 or hPAHT). Similar to the organic anion transporters from other species, hOAT1 functions as a PAH/dicarboxylate exchanger when transiently expressed in Xenopus laevis oocytes or HeLa cells. Despite one study suggesting a much narrower substrate specificity of hOAT1 compared to rROAT1 (11), we have shown that hOAT1 efficiently transports various acyclic nucleotide analogs including adefovir [9-(2-phosphonylmethoxyethyl)adenine] and cidofovir [(S)-1-(3-hydroxy-2-phophonylmethoxypropyl)cytosine], two clinically important antiviral therapeutics (9). Interestingly, hOAT1 showed markedly higher affinity toward this type of molecule than did rROAT1 (9).
Both adefovir and cidofovir are nucleoside phosphonate analogs, a class of novel antivirals structurally related to natural nucleotides (Figure 1). Cidofovir has been approved for the treatment of cytomegalovirus retinitis in AIDS patients (12), and adefovir dipivoxil, an orally available prodrug of adefovir, is currently undergoing clinical evaluation as an anti-HIV and anti-hepatitis B virus agent (13). Both drugs are actively secreted by the kidney (14,15), presumably via hOAT1, and for both of them, the main dose-limiting toxicity is nephrotoxicity (16,17). To reduce this adverse event, cidofovir is used in conjunction with probenecid, an inhibitor of organic anion transport (12). The organic anion transport system has also been implicated in the nephrotoxicity of other agents, for example, cephaloridine and cephaloglycin, two cephalosporin antibiotics (18), suggesting that hOAT1 may also be directly involved in the induction of nephrotoxicity associated with adefovir and cidofovir.
|
In an attempt to understand the involvement of hOAT1 in drug-induced nephrotoxicity, we studied the effect of hOAT1 expression on the transport, intracellular metabolism, and cytotoxicity of the two antiviral nucleotide analogs. Using a cell line stably expressing hOAT1, we have been able to demonstrate a direct role of hOAT1 in the etiology of organ-specific toxicity associated with adefovir and cidofovir.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Northern Blot Analysis
Total RNA was extracted from CHO and CHOhOAT cells using Trizol
Reagent (Life Technologies, Rockville, MD). After separation on 1.2% agarose
gel, RNA was transferred onto a Hybond-N membrane (Amersham Pharmacia Biotech,
Piscataway, NJ) and hybridized with hOAT1-specific 32P-labeled
probe (9) for 1 h at 68°C
in ExpressHyb hybridization buffer (Clontech). Subsequently, the membrane was
washed twice in 2x SSC with 0.05% sodium dodecyl sulfate for 30 min at
room temperature followed by a single wash in 0.1 x SSC with 0.1% sodium
dodecyl sulfate at 50°C. After autoradiography, the membrane was stripped
and reprobed with a ß-actin control probe (Clontech) under the same
conditions.
Transport Assays
The assays were carried out in 12-well plates with nearly confluent cells
seeded 48 h before each experiment. On the day of the experiment, growth
medium was aspirated and the cells were washed twice with phosphate-buffered
saline (PBS). The uptake of radiolabeled substrates was determined at 37°C
in Waymouth buffer (135 mM NaCl, 5 mM KCl, 2.5 mM CaCl2, 1.2 mM
MgCl2, 0.8 mM MgSO4, 28 mM glucose, and 13 mM Hepes, pH
7.2). At the end of incubation, the cells were washed 3 times with ice-cold
PBS (2 ml/well) and lysed directly on the plate by adding 0.3% Triton X-100
(0.5 ml/well) for 15 min. Subsequently, the wells were washed with an
additional 0.5 ml of the detergent, the lysate and wash were combined, and the
radio-activity in each sample was determined after addition of scintillation
fluid (Beckman Instruments, Fullerton, CA). In parallel plates, the number of
cells was determined and the substrate uptake was expressed as
pmol/106 cells. For determination of transport kinetics, the assays
were performed at various substrate concentrations, and the kinetic constants
were estimated by the linear regression from double reciprocal plots using
Enzyme Kinetics software (ChemSW, Fairfield, CA). Inhibition experiments were
carried out in the presence of various inhibitor concentrations at the
substrate concentration equal to its Km. Fifty percent
inhibitory concentration (IC50) values were estimated from
semilogarithmic plots of inhibitor concentration versus percentage of
uptake relative to uninhibited control.
Intracellular Metabolism
Confluent CHO and CHOhOAT cells in 6-well plates were incubated
in phenol red-free growth medium containing 5 µM [3H]adefovir or
10 µM [14C]cidofovir. After 12 h at 37°C, the cells were
washed 3 times with 3 ml of ice-cold PBS and extracted with 0.5 ml 5% TCA as
described previously (21). The
number of cells was determined in parallel samples incubated with unlabeled
drugs under identical conditions. The extracts were analyzed using a Separon
SGX C18 HPLC column (Melcor Technologies, Sunnyvale, CA) with a linear
gradient of acetonitrile (0 to 20% over 40 min at 1 ml/min) in the presence of
50 mM potassium phosphate, pH 7.0, and 3 mM t-butylammonium hydrogen
sulfate. One-milliliter fractions were collected, and the amount of
3H- or 14C-radioactivity was determined after addition
of 6 ml of scintillation fluid (Beckman Instruments). The identity of each
radioactive metabolite was confirmed by comparison of its retention time with
that of a corresponding unlabeled standard, and by HPLC analysis of extracts
treated with alkaline phosphatase or phosphodiesterase I as described
previously (22).
Drug Cytotoxicity Assays
CHO and CHOhOAT cells were seeded in parallel into 96-well
plates at a density of 3 x 103 cells/well. After 24 h,
various concentrations of the tested drugs were added in triplicate, and the
cells were incubated for an additional 120 h. At the end of the incubation,
cell viability was determined by a modified colorimetric assay using
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT; Sigma, St.
Louis, MO) (23). Briefly,
medium with the drug was removed and replaced by fresh medium (200 µl/well)
containing 0.1 mg/ml MTT. After a 90-min incubation at 37°C, the medium
was aspirated and the cells were extracted with 150 µl/well of DMSO. The
concentration of the extracted formazan metabolite was determined by
measurement of the absorbance at 560 nm (A560) in a 96-well plate
reader. Average A560 values were calculated from triplicates after
subtraction of the blank values, and the 50% cytotoxic concentration of each
drug (CC50) was determined from a semilogarithmic plot of drug
concentration versus percentage of A560 relative to
untreated control.
Materials
[3H]PAH (3.7 Ci/mmol) was obtained from Dupont New England
Nuclear (Boston, MA). [3H]9-(2-phosphonylmethoxyethyl)adenine
(adefovir; 30 Ci/mmol),
[14C](S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine
(cidofovir; 56 mCi/mmol), and [14C] [((S)-1 to
2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine (cyclic prodrug
of cidofovir; 55 mCi/mmol) were purchased from Moravek Biochemicals (Brea,
CA). Nonradioactive adefovir, cidofovir, and cyclic prodrug of cidofovir were
synthesized at Gilead Sciences according to previously published procedures
(24). Nonradioactive PAH,
probenecid, N-benzoyl-ß-alanine (betamipron), and glutarate were
obtained from Sigma.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
After transfection with the pIRES-hOAT plasmid, a number of G418-resistant CHO clones were isolated and assayed for PAH uptake in the presence and absence of probenecid. A transfectant of CHO cells capable of accumulating PAH to a level more than 30-fold higher than that determined in CHO cells was identified and designated CHOhOAT. Northern analysis with a hOAT1-specific DNA probe detected a 5-kb bicystronic transcript (containing both the hOAT1 and G418-resistance marker sequences) in the RNA extract from CHOhOAT, but not CHO cells, indicating the specific expression of hOAT1 in the stably transfected cells (Figure 2A). The uptake of PAH into CHO cells stably transfected with the empty pIRESneo vector (CHOpIRES) was similar to that determined for parental CHO cells (Figure 2B). Preloading CHOhOAT cells with 5 mM glutarate, a counterion accepted by the renal organic anion transporter (1), trans-stimulated PAH uptake; thus, the stably expressed hOAT1 functions as a PAH/dicarboxylate exchanger (Figure 2B).
|
Inhibition experiments (Figure 2C) showed that probenecid efficiently blocks the uptake of PAH by CHOhOAT cells with an IC50 value of 6.5 ± 1.0 µM (n = 3). Betamipron (N-benzoyl-ß-alanine) also inhibited hOAT1-mediated PAH uptake, but was less potent than probenecid with an IC50 of 16.2 ± 2.9 µM (n = 3).
High Efficiency of Adefovir and Cidofovir Transport Mediated by
hOAT1
In addition to PAH, CHOhOAT cells exhibited efficient
intracellular accumulation of adefovir and cidofovir. As shown in
Figure 3A, hOAT1-mediated
uptake of adefovir was linear during the initial 20 min. After 60 min,
adefovir accumulated in CHOhOAT cells to a level almost 80-fold
higher than that detected in parental CHO cells under the same conditions.
Uptake of cidofovir into CHOhOAT cells showed similar
characteristics (data not shown). Efficiency of hOAT1-mediated uptake of
nucleotide analogs and PAH was compared in transport kinetic experiments. To
approximate the initial rate of uptake, the experiments were carried out
within 3 min. Under these conditions, Km values of 15.4,
23.8, and 58.0 µM were determined for PAH, adefovir, and cidofovir,
respectively, indicating a slightly lower affinity of hOAT1 for nucleotide
analogs compared to PAH (Table
1). In contrast, the Vmax values for the
uptake of the nucleotide analogs were higher than that for PAH, resulting in
comparable efficiencies (i.e., Vmax/Km
ratio) of hOAT1-mediated uptake of all substrates. Interestingly, the cyclic
prodrug of cidofovir (Figure 1)
was also a substrate for hOAT1, even though one of the negative charges in the
molecule is blocked by an intramolecular ester bond. However, compared with
cidofovir, hOAT1-mediated uptake of the cyclic prodrug showed a significantly
higher Km and lower Vmax, resulting in
an almost 15-fold decrease in the transport efficiency for this molecule
(Table 1).
|
|
Similar to what was observed with PAH, the hOAT1-mediated uptake of adefovir was trans-stimulated by preloading CHOhOAT cells with glutarate. Optimization of the preloading conditions showed maximal stimulation of adefovir uptake after a 2-h preincubation of CHOhOAT cells in Waymouth buffer containing 5 mM glutarate. Under these conditions, preloading resulted in an approximately threefold increase in the efficiency of hOAT1-mediated uptake of adefovir (Figure 3B).
Based on the observation that hOAT1 is able to transport molecules that differ in terms of their net charge, we studied the pH dependence of hOAT1-mediated uptake of adefovir and PAH by performing the transport assay at pH values ranging from 5 to 9. As shown in Figure 4, PAH uptake was highest at pH 5 to 6. In contrast, adefovir showed highest accumulation in CHOhOAT cells at pH 6.5 to 7.5. At pH > 8, there was only very limited uptake (<15% of that at pH optimum) of both PAH and adefovir by CHOhOAT cells.
|
Metabolism of Adefovir and Cidofovir in CHOhOAT Cells
As analogs of nucleoside monophosphates, both adefovir and cidofovir are
intracellularly metabolized to the corresponding mono- and diphosphoryl
derivatives
(22,25,26).
In addition, cidofovir forms an adduct with choline, cidofovir-phosphocholine
(22). Although the metabolism
of both nucleotide analogs has been extensively studied in a variety of cell
types, the mechanism of cellular uptake in the vast majority of these models
was fluid-phase endocytosis
(27,28,29),
and none of the investigated cells apparently expressed hOAT1. In addition,
highly efficient uptake of adefovir and cidofovir via hOAT1 may result in the
saturation of intracellular metabolism with subsequent changes in the
proportions of metabolites.
To explore the effect of hOAT1 expression on the intracellular metabolism of the two nucleotide analogs, CHO and CHOhOAT cells were incubated for 12 h with 5 µM [3H]adefovir or 10 µM [14C]cidofovir followed by analysis of the metabolites. The total intracellular accumulation of adefovir and cidofovir was almost 140-fold and 190-fold higher, respectively, in CHOhOAT cells compared with CHO cells (Table 2). The levels of all adefovir metabolites in CHOhOAT increased proportionally to the total drug accumulation, with adefovir-diphosphate being the most abundant metabolite both in CHOhOAT and CHO cells. In contrast, the most abundant metabolite of cidofovir was cidofovir-phosphocholine. A more than 100-fold increase in the level of each cidofovir and adefovir metabolite upon hOAT1 expression indicated that nucleotide analogs, and presumably also the other substrates taken up via hOAT1, are subjected to the intracellular metabolism similar to that observed in hOAT1-negative cells.
|
Selective Cytotoxicity of Adefovir and Cidofovir in Cells Expressing
hOAT1
Consistent with the limited intracellular accumulation of adefovir and
cidofovir, CHO cells exhibited a relatively low susceptibility to the
cytotoxic effects of the two drugs. Thus, we investigated whether the enhanced
intracellular uptake and metabolism of both nucleotide analogs due to hOAT1
expression would translate into increased susceptibility of CHOhOAT
cells toward the two drugs. Both CHO and CHOhOAT cells were
incubated for 5 d with various concentrations of adefovir or cidofovir, and
the cytotoxic effect was determined by MTT colorimetric assay. As shown in
Figure 5A, both nucleotide
analogs were markedly more cytotoxic in CHOhOAT cells compared with
CHO cells. In the case of adefovir, expression of hOAT1 enhanced its
cytotoxicity approximately 500-fold. Similarly, cidofovir showed 400-fold
higher cytotoxicity in CHOhOAT cells compared with CHO cells. In
contrast, CHOhOAT cells were only fourfold more susceptible to the
cyclic prodrug of cidofovir, which corresponds with the low efficiency of
hOAT1-mediated uptake of this compound.
|
To address whether hOAT1 expression can also induce the cytotoxicity of adefovir and cidofovir in other cell types, Chinese hamster lung fibroblasts (V-79) were also stably transfected with hOAT1 cDNA. A transfectant of V-79 cells exhibiting >50-fold enhancement in the uptake of adefovir was isolated and its susceptibility to nucleotide analogs was compared with parental V-79 cells. Figure 5B shows that hOAT1 expression in V-79 cells also caused a marked shift in the susceptibility to adefovir and cidofovir, but not to the cyclic prodrug of cidofovir.
hOAT1-Mediated Cytotoxicity Is Reduced by Probenecid and
Betamipron
Similar to PAH, the uptake of nucleoside phosphonate analogs by
CHOhOAT cells was inhibited in the presence of the hOAT1 inhibitors
probenecid and betamipron (Figure
6). Both compounds showed similar inhibitory potency with
IC50 values of 7.0 ± 2.7 µM (n = 2) and 6.0
± 1.3 µM (n = 3), respectively, against adefovir, and 5.6
± 0.3 µM (n = 2) and 4.5 ± 0.8 µM (n =
2), respectively, against cidofovir, suggesting that they may have a
protective effect against hOAT1-mediated cytotoxicity of the nucleotide
analogs. Therefore, the cytotoxicity of adefovir and cidofovir was determined
simultaneously in the presence or absence of 1 mM probenecid. At this
concentration, probenecid itself showed no cytotoxicity either in CHO or
CHOhOAT cells. Notably, the CC50 values of adefovir in
CHOhOAT cells in the presence and absence of probenecid were 16 and
0.33 µM, respectively, accounting for an approximately 50-fold reduction in
the drug cytotoxicity (Table
3). Similarly, probenecid also decreased the cytotoxic effect of
cidofovir in CHOhOAT cells. In parental CHO cells, a slight
increase (two- to fourfold) in the cytotoxicity of adefovir and cidofovir was
observed in the presence of probenecid. This may be due to the effect of
probenecid on efflux of both drugs from CHO cells, since probenecid has been
shown previously to interfere with cellular efflux of various organic anions
(30,31).
Consequently, in the presence of probenecid, adefovir and cidofovir were only
2.5-fold and 4-fold more cytotoxic, respectively, in CHOhOAT cells
than in CHO cells. Betamipron, in accordance with its inhibitory effect on
hOAT1-specific transport, also markedly reduced hOAT1-mediated cytotoxicity of
both nucleotide analogs (Table
3).
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Kinetic experiments carried out using CHOhOAT cells demonstrated that the efficiency (Vmax/Km ratio) of hOAT1-specific uptake of adefovir and cidofovir is comparable to that of PAH. Consistent with the proposed function of hOAT1 as an organic anion/dicarboxylate exchanger, hOAT1-specific uptake of PAH and adefovir in CHOhOAT cells was trans-stimulated by glutarate. Further functional characterization of hOAT1 demonstrated a marked dependence of its transport activity on extracellular pH. The uptake of PAH and adefovir showed different pH optima, most likely reflecting the differences in the ionization of the two substrates. Comparison of pKa estimates for the carboxyl moiety of PAH (pKa = 3.2) and the phosphonate moiety of adefovir (pKa2 = 7.8) (32) is consistent with the lower pH optimum of PAH uptake and supports previous findings demonstrating a direct relationship between the pKa values of various organic anions and their interference with PAH uptake in isolated kidney proximal tubules (33). Notably, both the uptake of adefovir and PAH were almost completely suppressed at pH >8. This effect is opposite to that observed with some of the organic cation transporters. For example, transport activity of placental organic cation transporter type 3 is highest at pH >8, but is almost completely abolished at pH <6 due to the electrogenic character of the transporter, which makes it strongly sensitive to changes in the membrane potential induced by a shift to acidic pH (34). Because the sharp decline in hOAT1 transport activity at higher pH could not be explained only by the suppression of charge-charge interactions between the substrate and hOAT1, a further electrophysiologic characterization of hOAT1 is necessary to explore its sensitivity to membrane potential and fully explain the observed pH dependence.
The finding that the efficiency of hOAT1-mediated uptake of adefovir and cidofovir is as high as that of PAH supports the proposed role of hOAT1 in the mechanism of nephrotoxicity associated with the two antiviral nucleotides. However, in this study, we have also obtained direct evidence of the involvement of hOAT1 in the organ-specific toxicity induced by adefovir and cidofovir. After comparing the cytotoxic effect of both drugs in parental cells and cells stably expressing hOAT1, we concluded that hOAT1 expression markedly increases the sensitivity of cells to the cytotoxic effect of the two antivirals. This sensitivity increase appears to be proportional to the elevation of intracellular metabolites of adefovir and cidofovir in cells expressing hOAT1.
Based on the observed differences in the metabolism of adefovir and cidofovir, the intracellular target associated with their toxicity may be unique for each compound despite their close structural similarity. In the case of cidofovir, the major metabolite in CHOhOAT cells is cidofovir-phosphocholine, an analog of the phospholipid synthesis intermediate cytidine 5'-diphosphocholine. At high intracellular concentrations generated upon hOAT1 expression, this metabolite may possibly interfere with synthesis or degradation of membrane phospholipids, similar to what has been shown with arabinofuranosylcytosine 5'-diphosphocholine (35). In contrast, adefovir, which is an adenine nucleotide analog, undergoes only mono- and diphosphorylation in all cells tested thus far (13). Hence, following the accumulation via hOAT1, the drug itself or some of its metabolites may interfere with ATP synthesis, specific ATP-dependent processes, and/or transport of adenine nucleotides in various cellular compartments, e.g., the Golgi (36) or mitochondria (37).
It is important to recognize that in vivo, the hOAT1-mediated cytotoxic effect of adefovir and cidofovir in proximal tubules may not be as dramatic as that seen in our cell culture model due to the secretion of these two drugs from the tubular epithelium into the lumen as demonstrated by pharmacokinetic studies (14,15). Recently, the presence of multidrug resistance protein 2 (MPR2) in the apical membrane of human proximal tubules has been demonstrated (38). MRP2 is an ATP-dependent efflux pump for organic anion substances, and thus may mediate the apical efflux of adefovir and cidofovir into the lumen. For most substrates of the classical organic anion transport system, basolateral uptake appears to be the rate-limiting step in the entire tubular secretion pathway. However, an accumulation of cidofovir in the superficial kidney cortex, where proximal tubules are located, has been detected previously (39), indicating that the luminal efflux is most likely the limiting step in the tubular secretion of nucleoside phosphonates. Thus, in addition to highly efficient basolateral uptake, the slower rate of apical secretion may be another factor involved in the mechanism of nephrotoxicity associated with cidofovir and adefovir.
We demonstrated that the cytotoxicity enhancement upon hOAT1 expression is cell type-independent, because a similar effect was observed both in the cells of epithelial origin (CHO) and in fibroblasts (V-79). In vivo, high-level expression of hOAT1 has been detected specifically in kidney (9,10) corresponding with the kidney-specific toxicity of adefovir and cidofovir. However, based on sensitive detection using reverse transcription-PCR, the presence of a hOAT1-specific transcript has also been detected in skeletal muscles and brain (9). In skeletal muscles, only a truncated form of hOAT1-specific mRNA has been found, suggesting the expression of a modified form of hOAT1 that may lack or may have altered transport activity. This hypothesis correlates with the observed lack of accumulation of cidofovir in skeletal muscles as well as with the lack of the muscle-specific toxicity of the two antiviral nucleotides (39). In contrast, detection of the full-length hOAT1-specific mRNA in brain suggests expression of the active transporter. Indeed, probenecid-sensitive active transport of PAH and a variety of other organic anions has been detected previously in the choroid plexus of several mammalian species (40,41). However, both cell culture (42) and in vivo experiments (43) suggest that the organic anion transport activity in the choroid plexus is localized apically rather than basolaterally and participates in the active secretion of anionic drugs from cerebrospinal fluid into the systemic circulation. The apical membrane localization of hOAT1 would preclude its active role in organ-specific drug toxicity correlating with the lack of neurotoxicity of adefovir and cidofovir. Nevertheless, the precise localization and function of hOAT1 in brain remains to be confirmed by molecular and immunohistochemical analysis.
Characterization of the effect of hOAT1 expression on uptake and cytotoxicity of the cyclic prodrug of cidofovir provided additional support for the involvement of hOAT1 in the mechanism of drug-associated nephrotoxicity. The efficiency of hOAT1-mediated uptake of the prodrug was 15-fold lower than that of cidofovir, presumably due to differences in the polarity of the two molecules. Accordingly, the cytotoxicity of the prodrug was enhanced only three- to fourfold by hOAT1 expression compared to 400-fold enhancement determined for cidofovir under identical conditions. This observation strongly correlates with significantly lower renal accumulation of the cyclic prodrug as well as with its much lower nephrotoxic potential in various species compared to cidofovir (44,45).
Finally, the uptake of adefovir and cidofovir in CHOhOAT cells was sensitive to probenecid and betamipron, two potent hOAT1 inhibitors, which have exhibited in vivo nephroprotective effects against various nephrotoxic organic anions (46,47,48). Both compounds protected CHOhOAT cells from hOAT1-induced cytotoxicity of both nucleotide analogs. In fact, probenecid showed a corresponding nephroprotective effect in cynomolgus monkeys treated with cidofovir (49) and is currently used in conjunction with cidofovir therapy in AIDS patients to reduce the potential for nephrotoxicity.
In conclusion, using a cell line stably expressing hOAT1, we have extended the functional characterization of this physiologically important renal transport protein and have provided compelling evidence that hOAT1 plays a key role in the mechanism of organ-specific toxicity associated with adefovir and cidofovir antiviral therapy. In addition, the presented data support the utility of this in vitro model to explore the involvement of hOAT1 in the nephrotoxicity of other agents, to study potential drug-drug pharmacokinetic interactions and mechanisms of renal drug secretion, and to screen for inhibitors that could serve as efficient nephroprotectants.
|
Acknowledgments |
|---|
We thank Norbert Bischofberger, Mick Hitchcock, and Jay Toole of Gilead Sciences for helpful discussions and critical reading of the manuscript.
|
Footnotes |
|---|
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  N. Fontsere, C. Guerrero, V. Esteve, M. Sole, and M. R. de Arellano Proximal tubular dysfunction associated with tenofovir in an HVC-HIV co-infected patient undergoing HVC therapy NDT Plus, August 1, 2008; 1(4): 271 - 272. [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Rayner, P. Chanu, R. Gieschke, L. M. Boak, and E. N. Jonsson Population Pharmacokinetics of Oseltamivir When Coadministered With Probenecid J. Clin. Pharmacol., August 1, 2008; 48(8): 935 - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Saji, R. Kikuchi, H. Kusuhara, I. Kim, F. J. Gonzalez, and Y. Sugiyama Transcriptional Regulation of Human and Mouse Organic Anion Transporter 1 by Hepatocyte Nuclear Factor 1 {alpha}/{beta} J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 784 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mizuno, T. Takahashi, H. Kusuhara, J. D. Schuetz, T. Niwa, and Y. Sugiyama Evaluation of the Role of Breast Cancer Resistance Protein (BCRP/ABCG2) and Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in The Urinary Excretion of Sulfate and Glucuronide Metabolites of Edaravone (MCI-186; 3-Methyl-1-phenyl-2-pyrazolin-5-one) Drug Metab. Dispos., November 1, 2007; 35(11): 2045 - 2052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Young, K. Buchacz, R. K. Baker, A. C. Moorman, K. C. Wood, J. Chmiel, J. T. Brooks, and HIV Outpatient Study Investigators Renal Function in Tenofovir-Exposed and Tenofovir-Unexposed Patients Receiving Highly Active Antiretroviral Therapy in the HIV Outpatient Study J Int Assoc Physicians AIDS Care (Chic Ill), September 1, 2007; 6(3): 178 - 187. [Abstract] [PDF]
|
|
|
|
|
|
N. Mizuno, T. Takahashi, Y. Iwase, H. Kusuhara, T. Niwa, and Y. Sugiyama Human Organic Anion Transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) Transport Edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and Its Sulfate Conjugate Drug Metab. Dispos., August 1, 2007; 35(8): 1429 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Takenaka, J. A. Morgan, G. L. Scheffer, M. Adachi, C. F. Stewart, D. Sun, M. Leggas, K. F.K. Ejendal, C. A. Hrycyna, and J. D. Schuetz Substrate Overlap between Mrp4 and Abcg2/Bcrp Affects Purine Analogue Drug Cytotoxicity and Tissue Distribution Cancer Res., July 15, 2007; 67(14): 6965 - 6972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kazory, S. Singapuri, A. Wadhwa, and A. A. Ejaz Simultaneous development of Fanconi syndrome and acute renal failure associated with cidofovir J. Antimicrob. Chemother., July 1, 2007; 60(1): 193 - 194. [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Streetman Clinical Pharmacogenetics of the Major Adenosine Triphosphate Binding Cassette and Solute Carrier Drug Transporters Journal of Pharmacy Practice, June 1, 2007; 20(3): 219 - 233. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Imaoka, H. Kusuhara, M. Adachi, J. D. Schuetz, K. Takeuchi, and Y. Sugiyama Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir Mol. Pharmacol., February 1, 2007; 71(2): 619 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hasegawa, H. Kusuhara, M. Adachi, J. D. Schuetz, K. Takeuchi, and Y. Sugiyama Multidrug Resistance-Associated Protein 4 Is Involved in the Urinary Excretion of Hydrochlorothiazide and Furosemide J. Am. Soc. Nephrol., January 1, 2007; 18(1): 37 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Vidal, J. C. Domingo, J. Guallar, M. Saumoy, B. Cordobilla, R. Sanchez de la Rosa, M. Giralt, M. L. Alvarez, M. Lopez-Dupla, F. Torres, et al. In Vitro Cytotoxicity and Mitochondrial Toxicity of Tenofovir Alone and in Combination with Other Antiretrovirals in Human Renal Proximal Tubule Cells Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3824 - 3832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tahara, H. Kusuhara, K. Maeda, H. Koepsell, E. Fuse, and Y. Sugiyama INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECID Drug Metab. Dispos., May 1, 2006; 34(5): 743 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Bakhiya, M. Stephani, A. Bahn, B. Ugele, A. Seidel, G. Burckhardt, and H. Glatt Uptake of Chemically Reactive, DNA-Damaging Sulfuric Acid Esters into Renal Cells by Human Organic Anion Transporters J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1414 - 1421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bleasby, L. A. Hall, J. L. Perry, H. W. Mohrenweiser, and J. B. Pritchard Functional Consequences of Single Nucleotide Polymorphisms in the Human Organic Anion Transporter hOAT1 (SLC22A6) J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 923 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Kearney, S. Ramanathan, A. K. Cheng, R. Ebrahimi, and J. Shah Systemic and Renal Pharmacokinetics of Adefovir and Tenofovir Upon Coadministration J. Clin. Pharmacol., August 1, 2005; 45(8): 935 - 940. [Abstract] [Full Text] [PDF]
|
|
), and the substrate uptake was
determined. The data represent a mean of duplicates in a representative
experiment. In all cases, standard error was <5% of the uptake in the
absence of inhibitor.
) and CHOhOAT
([UNK]) cells were incubated with 25 µM [3H]adefovir for 5 to 60
min at 37°C. The uptake was terminated by washing the cells with ice-cold
PBS, and the samples were processed as described in Materials and Methods. The
inset shows uptake of adefovir into CHOhOAT cells during the
interval of 0 to 5 min under the same conditions. The data represent a mean of
duplicates in a representative experiment. (B) Stimulation of hOAT-mediated
uptake of adefovir by glutarate preloading. CHOhOAT cells were
incubated in Waymouth buffer in the absence or presence of 5 mM glutarate for
2 h. After extensive washing, 3-min uptake of 25 µM [3H]adefovir
has been determined as described in Materials and Methods. The data are means
± SEM from two independent experiments.
) or 25 µM [3H]adefovir (
) in Waymouth
buffer at various pH, and the intracellular substrate accumulation was
determined after 3 min. Phosphate buffer ([UNK],
